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Two-Year Clinical, Angiographic, and Intravascular
Ultrasound Follow-Up of the XIENCE V Everolimus-Eluting
Stent in the Treatment of Patients With De Novo Native
Coronary Artery Lesions
The SPIRIT II Trial
Bimmer E. Claessen, MD; Marcel A. Beijk, MD; Victor Legrand, MD; Witold Ruzyllo, MD;
Antonio Manari, MD; Olivier Varenne, MD, PhD; Maarten J. Suttorp, MD, PhD;
Jan G.P. Tijssen, PhD; Karine Miquel-Hebert, PhD; Susan Veldhof, RN;
Jose P.S. Henriques, MD, PhD; Patrick W. Serruys, MD, PhD; Jan J. Piek, MD, PhD
Background—This article reports the 2-year clinical, angiographic, and intravascular ultrasound outcomes of the
everolimus-eluting stent (EES) compared with the paclitaxel-eluting stent (PES) in the randomized SPIRIT II trial.
Methods and Results—This was a prospective, single-blind clinical trial in which a total of 300 patients with de novo
native coronary artery lesions were randomized to either EES or PES in a 3:1 fashion. Clinical follow-up was planned
at 2 years in all patients. A subset of 152 patients underwent serial angiographic and intravascular ultrasound analyses
at 6 months and 2 years. After 2 years, target lesion failure (cardiac death, myocardial infarction, and ischemia-driven
target lesion revascularization) rates were 6.6% and 11% in EES and PES, respectively (P0.31). At 6 months, a
significant reduction in angiographic in-stent late loss and percentage volume obstruction measured by intravascular
ultrasound was observed in the EES group. However, at 2-year follow-up, a late increased intimal hyperplasia growth
after implantation of an EES was observed. There were no significant differences between EES and PES for in-stent late
loss (EES, 0.330.37 mm versus PES, 0.340.34 mm; P0.84) and percentage volume obstruction (EES, 5.186.22%
versus PES, 5.806.31%; P0.65) at 2 years. The incidence of stent thrombosis was low and comparable in both
groups (EES, 0.9%; PES, 1.4%).
Conclusions—Although the previously reported angiographic and clinical superiority of the EES has vanished over time,
this report confirms and extends the previously demonstrated noninferiority in terms of in-stent late loss of the EES
when compared with the PES up to 2-year follow-up. There were no significant differences between EES and PES in
clinical, angiographic and intravascular ultrasound outcomes at 2 years. (Circ Cardiovasc Intervent. 2009;2:339-347.)
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Stenting of de novo lesions in native coronary arteries is anestablished and effective treatment of coronary narrow-
ing due to atherosclerosis. However, long-term efficacy of
bare metal stents (BMS) has been hampered by the develop-
ment of restenosis, resulting in rehospitalization for percuta-
neous or surgical revascularization in 10% to 20% of pa-
tients.1 Drug-eluting stents (DES) have been shown to be
effective against restenosis by reducing neointimal hyperpla-
sia after vascular injury, when compared with BMS.2
Clinical Perspective on p 347
The objective of the SPIRIT II trial was to evaluate the
safety and performance of the everolimus-eluting coronary
stent (XIENCE V, Abbott Vascular, Santa Clara, Calif)
compared with the paclitaxel-eluting coronary stent (TAXUS
EXPRESS2 or Liberte, Boston Scientific, Natick, Mass) in
the treatment of de novo native coronary artery lesions. The
everolimus-eluting stent (EES) is comprised of the ACS
MULTI-LINK VISION stent and delivery system and a
drug-eluting coating. Everolimus, an analogue of rapamycin,
is a powerful antiproliferative agent that blocks cell cycle
progression between the G1 and S phases, inhibiting smooth
muscle cell proliferation.3 The feasibility of the EES was first
demonstrated in the FUTURE-I and FUTURE II studies and
more recently in the SPIRIT FIRST study, which demon-
strated both clinical safety and efficacy.4–7 In the SPIRIT
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FIRST study, the clinical outcome at 2-year follow-up was in
favor of the EES group compared with the BMS group but did
not reach statistical significance because of small patient
numbers.
In this trial, the EES performed superior to the paclitaxel-
eluting stent (PES) regarding angiographic late loss at 6
months (0.110.27 versus 0.360.39 mm). Furthermore,
intravascular ultrasound (IVUS) results showed that the EES
was more effective at reducing neointimal hyperplasia; both
percentage volume obstruction and neointimal hyperplasia
volume were significantly lower in patients treated with
EES.8 The incidence of target lesion failure (TLF) was low
and comparable between groups at 6 months (2.7% for EES
versus 6.5% for PES). At 1 year, there was a significant
benefit in TLF favoring the EES (2.7% versus 9.2%).9
This report focuses on the 2-year clinical outcomes of all
patients enrolled in the SPIRIT II trial and the angiographic
and IVUS follow-up in a subset of patients.
Methods
Study Population
The study design of the SPIRIT II trial has been previously
described.8–10 In brief, this prospective, randomized (3:1) single-
blind, parallel 2-arm trial was performed at 28 centers in Europe,
India, and New Zealand and randomized 300 patients in a 3:1 ratio
to either an EES (n223) or a PES (n77) between July 2005 and
November 2005. The study protocol was approved by the ethics
committee at each participating institution, and all patients gave
written informed consent.
Patients enrolled in the study were older than 18 years with
evidence of myocardial ischemia and had a maximum of 2 de novo
native coronary artery lesions, located in different major epicardial
vessels. Target lesions had to comply with the following inclusion
criteria: a reference vessel diameter between 2.5 and 4.25 mm by
visual estimation, a target lesion length 28 mm, a visually
estimated stenosis between 50% and 99% of the luminal diameter,
and a Thrombolysis In Myocardial Infarction flow grade of 1 or
more. Patients were excluded from enrollment if they had docu-
mented acute myocardial infarction within 3 days prior to the
baseline procedure, a left ventricular ejection fraction 30%, were
awaiting a heart transplant or had a known hypersensitivity or
contraindication to aspirin, heparin, bivalirudin, clopidogrel or ticlo-
pidine, cobalt, chromium, nickel, tungsten, everolimus, paclitaxel,
acrylic, and fluoropolymers. Angiographic exclusion criteria were
target lesions within 2 mm of the origin of the left anterior
descending or left circumflex coronary artery, heavy calcification, or
a visible thrombus within the target vessel.
Study Procedure
Following the confirmation of angiographic in- and exclusion criteria
before the procedure, patients were randomized through a telephone
call to either an EES or a PES. Because of packaging differences,
operators were not blinded to the device. Lesions were treated using
standard interventional techniques with mandatory predilatation and
stent implantation pressure not exceeding the burst pressure rate.
Postdilatation was left to the discretion of the physician, and if
performed was only to be done with balloons sized to fit within the
boundaries of the stent. In the event of a bailout procedure and
additional stent requirement, the stent had to be one from the same
group as the first implanted stent. At baseline, IVUS was performed
in a subset of 152 consecutive patients enrolled in preselected
centers, after angiographically optimal stent placement had been
obtained. IVUS was repeated if additional postdilatation was per-
formed to optimize stent apposition and/or deployment. Patient
preparation and pharmaceutical treatment during the hospital proce-
dure were to be in accordance with standard hospital practice. The
use of GPIIb/IIIa inhibitors was left to the discretion of the
physician. All patients were to receive 75 mg of clopidogrel for a
minimum of 6 months and 75 mg of aspirin daily for a minimum
of 1 year after the procedure.
Follow-Up
Clinical follow-up was scheduled at 30, 180, and 270 days and 1 and
2 years with further evaluations planned at 3, 4, and 5 years by
protocol amendment. At outpatient visits, patients were asked
specific questions about the interim development of angina or the
occurrence of adverse events. Angiographic follow-up was planned
at 180 days for all patients. In the subset of 152 consecutive patients
(enrolled in selected centers), IVUS was planned at 180 days and
both IVUS and angiographic follow-up were to be repeated at 2
years. There was a 28-day window for the visit at 2 years.
Clinical End Points
The clinical part of this 2-year follow-up study focuses on TLF
(cardiac death, myocardial infarction [MI], and ischemia-driven
target lesion revascularization [TLR], either by coronary artery
bypass graft or percutaneous coronary intervention—defined as
major adverse cardiac events in the study protocol). Secondary
clinical end points included target vessel failure (cardiac death, MI,
and ischemia-driven target vessel revascularization), TLR, target
vessel revascularization, and stent thrombosis. All clinical end points
were adjudicated by a blinded clinical events committee.
All deaths that could not be clearly attributed to a noncardiac
cause were considered cardiac deaths. Q-Wave MI was defined as
development of new pathological Q waves. Non–Q-wave MI was
defined as a typical rise and fall of creatine kinase-MB with at least
one of the following: ischemic symptoms, electrocardiographic
changes indicative of ischemia, or associated with a coronary artery
intervention. For nonprocedural/spontaneous MI, creatine kinase-
MB had to be 2 times the upper limit of normal, for postpercuta-
neous coronary intervention 3 times upper limit of normal, and for
postcoronary artery bypass grafting 5 times the upper limit of
normal. For each MI, the relationship to the target vessel was
adjudicated by the clinical events committee.
Ischemia-driven TLR was defined as a revascularization at the
target lesion associated with any of the following: a positive
functional ischemia study (exercise testing, fractional flow reserve,
or coronary flow reserve), ischemic symptoms, and an angiographic
diameter stenosis 50% by core laboratory quantitative coronary
angiography (QCA); or a diameter stenosis70% by core laboratory
QCA without ischemic symptoms or a positive functional study.
Stent thrombosis was categorized according to the definitions
proposed by the Academic Research Consortium for definite, prob-
able, and possible stent thrombosis.11
Angiographic End Points
The angiographic part of this article focuses on in-stent late loss at 2
years (in the subset of 152 patients). Secondary angiographic end
points include in-segment late loss, proximal and distal late loss,
in-stent and in-segment percentage diameter stenosis, and angio-
graphic binary restenosis.
QCA was performed using the CAAS II analysis system (Pie
Medical BV, Maastricht, The Netherlands) by an independent core
laboratory (Cardialysis BV, Rotterdam, The Netherlands) with ob-
servers blinded to treatment assignment. In each patient, the stented
segment and the peri-stent segments (defined by a length of 5 mm
proximal and distal to the stent edge) were analyzed. The following
QCA parameters were computed: minimal luminal diameter, refer-
ence vessel diameter obtained by an interpolated method, and
percentage diameter stenosis. Binary restenosis was defined in every
segment as a diameter stenosis 50% at follow-up. Late loss was
defined as the difference between minimal luminal diameter post-
procedure and minimal luminal diameter at follow-up. If a patient
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underwent TLR before the scheduled 2-year angiography, QCA was
performed on the preinterventional angiography, and its results were
imputed into 2-year follow-up angiography outcomes.
IVUS End Points
The IVUS part of this article focuses on percentage in-stent volume
obstruction at 2 years (in the subset of 152 patients). Secondary
IVUS end points include in-stent neointimal volume and vessel,
stent, and lumen volumes.
Postprocedure and follow-up stented vessel segments were exam-
ined with mechanical or phased array IVUS (Eagle-eye Volcano,
Rancho Cordova, Calif; Atlantis, Boston Scientific, Natick, Mass)
using automated pull-back at 0.5 mm per second after administration
of 0.2 mg intracoronary nitroglycerin. The coronary segment begin-
ning 5-mm distal to and extending 5-mm proximal to the stented
segment was examined. IVUS analyses were also performed by an
independent core laboratory (Cardialysis BV, Rotterdam, The Neth-
erlands) with observers blinded to treatment assignment. A
computer-based contour detection program was used for automated
3D reconstruction of the stented and adjacent segments. The lumen,
stent boundaries, and external elastic membrane (vessel boundaries)
were detected using a minimum cost algorithm.12 The stent volume
and lumen volume were calculated according to Simpson’s rule.13
The in-stent neointimal volume was calculated as the difference
between stent volume and lumen volume. The percentage obstruc-
tion of the stent volume was calculated as intrastent neointimal
volume/stent volume100. Feasibility, reproducibility, and inter-
and intra-observer variability of this system have been validated in
vitro and in vivo.13 Incomplete apposition was defined as one or
more stent struts separated from the vessel wall with evidence of
blood speckles behind the strut on ultrasound, whereas late-acquired
incomplete apposition was defined as incomplete apposition of the
stent at follow-up which was not present postprocedure.14–16
Statistical Methods
Final 2-year results are presented in this article. Six-month results in
patients whose 2-year results were available are presented for
comparative purposes. (These results may differ from those in
previous publications with more patients) Binary variables are
presented as percentages and compared using the Fisher exact test.
Continuous variables are presented as meanstandard deviation and
compared using the Student t test. Confidence intervals for the
differences are based on normal assumption. Noninferiority proba-
bility values for in-stent late-loss in the subset of lesions with serial
6 months and 2 years measurements are calculated with a 1-sided
asymptotic test and were not predefined in the protocol. The
noninferiority margin used for those tests is 0.16 mm, corresponding
to the prespecified margin for the primary end point analysis.8
Survival curves using all available follow-up data were also con-
structed for time-to-event variables using Kaplan–Meier estimates
and compared by log-rank test. Data on patients who were lost to
follow-up were censored at the time of the last contact. Data on
patients who died of noncardiac causes were censored at the time of
death. Statistical analyses were performed using SAS version 9.1.3
(SAS Institute Inc, Cary, NC).
Results
Patients and Enrollment
Two-year clinical follow-up was available for 211 of the 223
patients (94.6%) in the EES group and in 73 of the 77 patients
Figure 1. Patient flow chart and clinical, angio-
graphic, and intravascular ultrasound follow-up in
the SPIRIT II trial.
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(94.8%) of the PES group (Figure 1). In the EES group, 4
patients withdrew, 1 patient was lost to follow-up, and 7
patients died from a noncardiac cause. In the PES group with
no patients lost to follow-up, 4 patients died from a noncar-
diac cause. Baseline demographic, clinical, and angiographic
characteristics of the treatment groups have previously been
reported and are summarized in Table 1.8 There were no
significant differences between treatment groups in any of the
tabulated characteristics, with the exception of a smaller
minimal lumen diameter (MLD) in the EES group (P0.03).
Of the subset of 152 patients in the angiography and IVUS
subgroup, a further subset of 115 patients underwent serial
and analyzable angiography (EES, 97 lesions, 83 patients,
73%; PES, 35 lesions, 32 patients, 82%) and 95 patients
underwent serial and analyzable IVUS (EES, 69 lesions, 64
patients, 57%; PES, 32 lesions, 31 patients, 79%). The
angiography and IVUS patient subgroup was comparable
with the total cohort (data not shown). There were no
differences in baseline characteristics between the EES and
PES patient groups in the angiography and IVUS subset of
patients with the exception of a higher prevalence of previous
MI in the EES patient group (EES: 42%; PES: 18%, P0.01)
and a smaller MLD in the EES group (P0.01).
Clinical Outcomes
Table 2 shows target vessel failure (TLF) at 2 years and each
of its components. At 2 years, TLF occurred in 6.6% of the
EES group compared with 11.0% in the PES group. In each
treatment group, 1 patient died of a cardiac cause (0.5%
versus 1.4%). The incidence of MI at 2 years was 2.8% (6
patients) and 5.5% (4 patients) in the EES and PES groups,
respectively. Ischemia-driven TLR comprised the majority of
TLF within both groups with 3.8% (8 patients) and 6.8% (5
patients) in the EES and PES groups, respectively. The
temporal distribution of TLF and its component events is
shown in Kaplan–Meier curves (Figure 2). Although TLF
rates in the EES group are consistently lower, the significant
separation in TLF rate observed at 1 year was not maintained
at the 2-year follow-up (Plogrank0.223).
Definite or probable stent thrombosis occurred once in 2
patients (0.9%) in the EES treatment group and twice in one
patient (1.4%) in the PES treatment group. Both the stent
thromboses in the everolimus group occurred after 1 year.
Characteristics of the stent thrombosis episodes are shown in
Table 3.
Angiographic Outcomes
Angiographic results from 132 lesions in the subset of 115
patients who underwent serial angiography at 6 months and 2
years are shown in Table 4. Two-year mean in-stent late loss
was 0.330.37 mm for the EES group and 0.340.34 mm
for the PES group (P0.84) against 0.170.32 and





Patient characteristics, % (unless
otherwise specified)





Hypercholesterolemia-requiring medication 69 75
Diabetes mellitus 23 24
Current smoker 32 30
Prior myocardial infarction 35 25
Unstable angina 27 32
Target vessel, % NL260 NL91
Left anterior descending 41 47
Left circumflex 29 19
Right coronary artery 30 34
Target lesion characteristics, meanSD
Reference vessel diameter, mm 2.700.52 2.820.58
Minimal lumen diameter, mm 1.060.42 1.140.36
Diameter stenosis, % 6112 5910
Lesion length, mm 13.05.7 13.26.4
There were no significant differences in baseline variables between the
groups, with the exception of a smaller MLD in the EES group (P0.03).





Death 3.7 6.5 0.33
Cardiac death 0.5 1.4 0.45
MI related to target vessel 2.8 4.1 0.7
Q-wave 0 0 NA
Non–Q-wave 2.8 4.1 0.70
Any MI 2.8 5.5 0.29
Q-wave 0 0 NA
Non–Q-wave 2.8 5.5 0.29
Composite of cardiac death or MI* 3.3 5.5 0.48
ID TLR 3.8 6.8 0.33
Percutaneous 3.8 6.8 0.33
Surgical 0 0 NA
TLF* 6.6 11.0 0.31
Any TLR 4.6 9.1 0.16
Percutaneous 4.6 9.1 0.16
Surgical 0 0 NA
ID target vessel revascularization 7.1 9.6 0.46
Percutaneous 6.6 9.6 0.44
Surgical 0.5 0 1.00
TVF* 10.0 12.3 0.66
Any target vessel revascularization 8.7 11.7 0.50
Percutaneous 7.8 11.7 0.35
Surgical 0.9 0.0 1.00
Any repeat revascularization 15.6 15.1 1.00
P values were calculated using Fisher exact test. Denominators for TVF
components and any repeat revascularization are 211 for EES and 73 for PES;
denominators for other non-TVF components are 218 for EES and 77 for PES.
ID indicates ischemia driven; TVF, target vessel failure.
*Hierarchical.
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0.330.32 (P0.01) at 6 months. If we would apply the
noninferiority margin prespecified for the analysis of the
primary end point at 6 months of 0.16 mm, the results at 2
years would still show noninferiority (post hoc analysis).8
Figure 3 shows the cumulative distribution frequency curve
of in-stent late loss at 6-month and 2-year follow-up. Proxi-
mal and distal mean late loss were 0.240.49 and 0.080.38,
respectively, for EES and 0.330.45 and 0.110.40 for PES.
Mean in-stent percent diameter stenosis was 19.2114 in the
everolimus group compared with 18.7611 in the paclitaxel
group (P0.85). Two-year in-stent angiographic binary re-
stenosis rate was 2.1% for EES and 2.9% for PES (P1.000).
IVUS Outcomes
IVUS results from 101 lesions in 95 patients who underwent IVUS
at 6 months and 2 years are shown in Table 5. IVUS evaluation at
2-year follow-up showed no significant differences in per-
centage volume obstruction between EES and PES treatment
groups. Mean percentage volume obstruction was 5.186.22
versus 5.806.31 (P0.65) for EES and PES, respectively.
Similarly, the neointimal hyperplasia volume at 2 years did
not differ between both groups. Mean neointimal hyperplasia
volume was 8.4210.25 mm3 in the everolimus group and
11.5616.12 mm3 in the paclitaxel group. IVUS evaluation
showed no significant differences between EES and PES with
respect to vessel, stent, and lumen volumes at 2 years.
Discussion
This article reports the 2-year clinical, angiographic, and
IVUS follow-up of the EES compared with the PES in
patients with a maximum of 2 de novo coronary artery
lesions. The results of this trial confirm the efficacy of the
EES from earlier results reported in the FUTURE I and II and
SPIRIT FIRST, II, and III studies.4,6–10,17 In addition, this is
the first study that provides 2-year angiographic and IVUS
data for the EES. Two-year TLF rates in the current trial were
6.6% for the EES and 11.0% for the PES (P0.31).
To date, results from one other randomized clinical trial
comparing EES and PES are available. The large-scale
SPIRIT III trial enrolled 1002 patients in the North America
with a maximum of 2 de novo coronary artery lesions who
were randomized 2:1 to EES or PES. Inclusion and exclusion
criteria were similar to the SPIRIT II trial. As a result,
baseline variables were comparable between both trials; mean
lesion length was 13.0 and 14.7 mm, mean reference vessel
diameter was 2.7 and 2.8 mm for SPIRIT II and SPIRIT III,
respectively.9,17 In the SPIRIT III trial, at 2 years, TLF rates
remained significantly lower for the EES; 7.7% for EES and
13.8% for PES (P0.005),18 with continued divergence of
the event rates between 1 and 2 years. The reduced TLF rate
in the EES group was attributable to fewer non–Q-wave MIs
and TLRs. Although the difference in 2-year TLF rate did not
reach statistical significance in the current SPIRIT II trial, a
Figure 2. Cumulative distribution curves for 2-year and 180-day
in-stent late loss. The probability value for noninferiority of the EES
at 2 years was 0.005 (non prespecified analysis in this subgroup).
Table 3. Listing of Definite/Probable Stent Thrombosis During 2-Year Follow-Up
Patient





55-y-old man PES 9 Mid LAD Definite Yes Non–Q-wave No Yes
55-y-old man PES 56 Mid LAD Probable No Non–Q-wave Yes No
54-y-old man EES 538 Mid RCA Definite Yes Non–Q-wave No No
61-y-old man EES 721 Distal RCA Probable Yes Non–Q-wave No Yes
LAD indicates left anterior descending; RCA, right coronary artery.
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trend in favor of the EES was observed. The results of the
SPIRIT III trial indicate that this nonsignificance is most likely
due to the lower number of patients enrolled in SPIRIT II.
The incidence of definite or probable stent thrombosis as
defined by the Academic Research Consortium11 was 0.9%
for EES and 1.4% for PES after 2 years in the current study.
Two-year stent thrombosis rates have been reported for 3
randomized trials evaluating the EES, SPIRIT FIRST, II, and
III.4,18 In these 3 trials combined, 2-year follow-up data were
available for 866 patients treated with an EES. The occur-
rence of stent thrombosis was low; in total, 10 patients (1.2%)
had suffered a definite or probable stent thrombosis within
Table 4. Comparison of Angiographic Outcomes Between EES and PES at 6-Month and 2-Year Follow-Up
EES (83,* 97†) PES (32,* 35†) Difference 95% CI P
6-mo angiographic outcomes
Late loss (meanSD), mm
In-stent late loss 0.170.32 0.330.32 0.16 0.29,0.03 0.01
In-segment late loss 0.120.33 0.140.32 0.02 0.14, 0.11 0.79
Proximal late loss 0.200.41 0.280.43 0.08 0.25, 0.09 0.35
Distal late loss 0.080.35 0.060.35 0.01 0.12, 0.15 0.86
Diameter stenosis (meanSD), %
In-stent percent diameter stenosis 1611 1811 2 7, 2 0.28
In-segment percent diameter stenosis 2413 2613 2 7, 3 0.42
Binary angiographic restenosis, %
In-stent BAR 1.0 2.9 1.8% 0.46
In-segment BAR 3.1 5.7 2.6% 0.61
2-y angiographic outcomes
Late loss (meanSD), mm
In-stent late loss 0.330.37 0.340.34 0.01 0.15, 0.12 0.84
In-segment late loss 0.210.37 0.170.38 0.04 0.11, 0.19 0.63
Proximal late loss 0.240.49 0.330.45 0.09 0.27, 0.09 0.34
Distal late loss 0.080.38 0.110.40 0.03 0.19, 0.13 0.70
Diameter stenosis (meanSD), %
In-stent percent diameter stenosis 1914 1911 0 4, 5 0.85
In-segment percent diameter stenosis 2614 2714 1 6, 5 0.86
Binary angiographic restenosis, %
In-stent BAR 2.1 2.9 0.8 1.00
In-segment BAR 5.2 8.6 3.4 0.44
P values for continuous variables were calculated using Student t test, and P values for dichotomous variables were calculated
using Fisher exact test. BAR indicates binary angiographic restenosis.
*No. of patients.
†No. of lesions.
Figure 3. Kaplan–Meier curves of TLF and its components.
344 Circ Cardiovasc Intervent August 2009
 by guest on April 29, 2014http://circinterventions.ahajournals.org/Downloaded from 
2-year follow-up, indicating the safety of the EES up to
2-year follow-up. It must be born in mind that definitive
statements about long-term safety of the EES can only be
made after the results of larger registries have become
available.
Angiographic and IVUS data of DES are limited beyond 6-
to 9-month follow-up. At 6 months follow-up, in the sub-
group with 6-month and 2-year angiography from the SPIRIT
II trial the in stent late loss was 0.170.32 mm in the EES
group and 0.330.32 mm in the PES group (P0.01).
Furthermore, significant differences in neointimal hyperpla-
sia volume (4.136.77 versus 12.6216.77 mm3, P0.01)
and percentage volume obstruction (2.775.02% versus
6.486.69%, P0.01) in favor of the EES were observed. At
2 years, delayed neointimal hyperplasia was observed in the
EES group with an in-stent late loss measured by QCA of
0.330.37 mm, whereas the late loss measured in the PES
group was maintained (0.340.34 mm, P0.6). IVUS mea-
surements were in accordance with this as we no longer
observed significant differences in neointimal hyperplasia
volume (EES, 8.4210.25 mm3; PES, 11.5616.12 mm3)
and percentage volume obstruction (EES, 5.186.22%; PES,
5.806.31%) at 2 years. Given the small number of late
TLRs in this study one can only speculate whether the
delayed neointimal hyperplasia in the EES group did lead to
an increase in TLR.
Our results are in line with the results from the TAXUS II
trial, comparing slow- and moderate-release PES to a BMS in
patients with a single de novo coronary artery lesion, in which
6-month and 2-year angiographic and IVUS follow-up was
obtained in a subset of 155 event-free patients.14,19 Angio-
graphic late loss in the PES group was 0.250.30 mm at 2
years which was not different compared with 6-month late
loss (0.290.32 mm) and is consistent with the findings
reported in this article. Neointimal volume measured by
IVUS increased significantly from 6 months to 2 years for the
PES treatment group, whereas a trend toward a decrease was
observed in the BMS group. This is inconsistent with IVUS
observations in this trial, where neointimal volume remained
unchanged in the PES group between 6 months and 2 years.
Patients in the PES treatment group in the TAXUS II trial
were treated with a less advanced stent platform (NIR stent
platform) with 2 different drug release kinetics (slow and
moderate release), which could explain this discrepancy.
Previous animal studies already showed that despite
marked early suppression of neointimal formation, late neo-
intimal growth occurs within DES. In a porcine coronary
artery model, long-term inhibition of neointimal formation
after sirolimus-eluting stent placement was not maintained
partly due to inflammation and delayed cellular proliferation.
In addition, after PES placement similar findings were found
with delayed healing and local toxicity after high-dose
paclitaxel, which was associated with delayed intimal
formation.20,21
In vivo, the explanation for the delayed neointimal growth
is multifactorial. In addition to an inflammatory response,
shear stress-mediated remodeling could also attribute to the
late “catch-up” phenomenon observed in the EES group.22
Shear stress is a primary signal for neointimal growth and is
defined as the frictional force at the endothelial surface
produced by flowing blood. Regions with low shear stress in
the treated coronary segment have been found to be predis-
posed for neointimal growth.22 Differences in stent design
could have led to different distributions of shear stress after
stent placement. Finally, the differences in polymer and
pharmacological release kinetics between both stent types
could be another explanation. Everolimus is blended into an
8-m-thick durable fluoropolymer layer, 75% of the drug
on the EES is released within 30 days after implantation.
Paclitaxel is blended into an 18-m-thick polymer layer,
during the first 48 hours after PES implantation there is an
initial burst release followed by 10 days of continuous drug
release.
The longest available angiographic and IVUS follow-up
after DES is 4 years. From 2 to 4 years, neointimal growth
was still observed. However, delayed restenosis after DES
Table 5. Comparison of IVUS Outcomes Between EES and PES at 6-Month and 2-Year Follow-Up
EES (64,* 69†) PES (31,* 32†) Difference 95% CI P
6-mo IVUS outcomes, meanSD
In-stent neointimal volume, mm3 4.136.77 12.6216.77 8.49 14.72,2.25 0.01
In-stent volume obstruction, % 2.775.02 6.486.69 3.71 6.38,1.04 0.01
Vessel volume, mm3 330135 393154 63 128, 1 0.05
Stent volume, mm3 16371 18274 19 51, 12 0.22
Lumen volume, mm3 15971 17070 11 41, 19 0.47
2-y IVUS outcomes, meanSD
In-stent neointimal volume, mm3 8.4210.25 11.5616.12 3.14 9.40, 3.12 0.32
In-stent volume obstruction, % 5.186.22 5.806.31 0.62 3.31, 2.07 0.65
Vessel volume, mm3 332150 384158 51 119, 16 0.13
Stent volume, mm3 16268 18277 21 52, 11 0.20
Lumen volume, mm3 15365 17172 17 48, 13 0.25
P values for continuous variables were calculated using Student t test, and P values for dichotomous variables were calculated
using Fisher exact test.
*No. of patients.
†No. of lesions.
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implantation does not seem to have clinical significance as
both PES and sirolimus-eluting stent markedly reduce TLR
and target vessel revascularization after 4 years.2 We will
have to await the 3, 4, and 5 years clinical follow-up for the
SPIRIT II and III studies to evaluate the long-term clinical
implications for the EES. A preliminary analysis of the 3-year
data from SPIRIT II has in fact shown significantly lower
cardiac death and TLF event rates, and lower observed MI
and ischemia-driven TLR rates for EES compared with PES
(ACC 2009 abstract).23 Furthermore, the performance of the
EES will be evaluated in more complex patients in the
SPIRIT IV, V, XIENCE V SPIRIT Women, and XIENCE V
USA studies.
Study Limitations
This trial was not powered to detect significant differences in
the safety profiles of PES and EES. Given the low frequency
of the stent thromboses (3 patients total in this trial), no
conclusions can be made about the relative safety profile of
these stents. Furthermore, this was a single-blind trial. The
operator was aware of the type of stent being implanted.
However, it is unlikely that knowledge of the stent type
would have influenced the operators’ decisions to reinter-
vene. Angiographic data were obtained on roughly half the
cohort; serial analyses were performed on a further subset.
Finally, we need more prolonged clinical follow-up to
establish whether the late neointimal catch-up observed in
the EES treatment group translates into an increased
revascularization rate.
Conclusion
Although the previously reported angiographic and clinical
superiority of the EES has vanished over time, this report
confirms and extends the previously demonstrated noninferi-
ority in terms of in-stent late loss of the EES when compared
with the PES up to 2-year follow-up. There were no signifi-
cant differences between EES and PES in clinical, angio-
graphic, and IVUS outcomes at 2 years.
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CLINICAL PERSPECTIVE
Drug-eluting stents have been shown to significantly reduce the need for repeat percutaneous coronary intervention
compared with bare metal stents in percutaneous treatment of coronary artery disease. In the Clinical Evaluation of the
XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery
Lesions, Spirit II trial, a next-generation everolimus-eluting stent (EES) was compared with the paclitaxel-eluting stent in
300 patients. Angiographic and intravascular follow-up was available at 2 years in a subset of 115 patients. At 2-year
follow-up, a delayed neointimal hyperplasia was observed in the EES group. Two-year mean in-stent late loss was
0.330.37 mm for the EES group and 0.340.34 mm for the paclitaxel-eluting stent group (P0.84) versus 0.170.32
and 0.330.32 (P0.01) at 6 months. Despite this late catch-up in neointimal hyperplasia, no such trend in the composite
clinical end point of target lesion failure (consisting of cardiac death, myocardial infarction, and ischemia-driven target
lesion revascularization) was observed. At 2 years, target lesion failure rates were 6.6% for the EES group compared with
11.0% for the paclitaxel-eluting stent group (P0.31). We will have to await more prolonged clinical follow-up from this
study, and larger studies that are currently being performed to evaluate the long-term clinical implications of the observed
late neointimal hyperplasia catch-up in the EES.
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